Significant Ownership of ORBIMED ADVISORS LLC
- Signature - Title
- /s/ Carl L. Gordon - Carl L. Gordon/Member
- Location
- New York, NY
- Summary
- This page shows a list of all the recent SCHEDULE 13D/G filings made by ORBIMED ADVISORS LLC.
Follow Filing Activity
Follow ORBIMED ADVISORS LLC and return when a new Schedule 13D/G filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
Useful next steps after a schedule filing
Use the page below that answers the next obvious question about this reporting manager or security.
- Latest 13D/G reports to compare this manager with other current ownership disclosures.
- Latest insider ownership reports if you want insider activity alongside the beneficial ownership record.
- Latest 13F portfolio filings for broader institutional context.
- Latest investment quarter holder pages when the next step is security-level holder history.
Significant Ownership of ORBIMED ADVISORS LLC
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| PRLD | Prelude Therapeutics Inc | COMMON STOCK | 16% | $44,259,932 | 12,935,071 | ORBIMED ADVISORS LLC | 21 Apr 2026 | ||
| EWTX | Edgewise Therapeutics, Inc. | Common Stock | 14% | $234,894,152 | 15,252,867 | ORBIMED ADVISORS LLC | 09 May 2025 | ||
| ELVN | Enliven Therapeutics, Inc. | COMMON STOCK | 13% | $140,468,212 | 7,918,163 | ORBIMED ADVISORS LLC | 16 Jun 2025 | ||
| QTTB | Q32 Bio Inc. | COMMON STOCK | 13% | $13,292,623 | 2,252,987 | 0% | ORBIMED ADVISORS LLC | 05 May 2026 | |
| IMA | ImageneBio, Inc. | COMMON STOCK | 13% | $7,475,225 | 1,495,045 | ORBIMED ADVISORS LLC | 14 Apr 2026 | ||
| TRAW | Traws Pharma, Inc. | Common Stock | 12% | $3,431,754 | +$2,040,131 | 1,876,198 | +147% | ORBIMED ADVISORS LLC | 16 Apr 2026 |
| CRVS | CORVUS PHARMACEUTICALS, INC. | COMMON STOCK | 10% | $66,290,001 | -$9,057,756 | 8,609,091 | -12% | ORBIMED ADVISORS LLC | 23 Jan 2026 |
| XLO | Xilio Therapeutics, Inc. | Common Stock, par value $0.0001 per share | 10% | $5,399,220 | 642,000 | ORBIMED ADVISORS LLC | 31 Mar 2026 | ||
| STTK | Shattuck Labs, Inc. | Common Stock, par value $0.0001 per share | 10% | $5,107,963 | 6,306,127 | ORBIMED ADVISORS LLC | 25 Aug 2025 | ||
| CMPX | Compass Therapeutics, Inc. | COMMON STOCK | 8.9% | $41,093,984 | 15,219,994 | 0% | ORBIMED ADVISORS LLC | 13 Aug 2025 | |
| WHWK | Whitehawk Therapeutics, Inc. | Common Stock, par value $0.0001 per share | 8.9% | $6,415,640 | 4,166,000 | OrbiMed Advisors LLC | 31 Mar 2025 | ||
| ACET | Adicet Bio, Inc. | Common Stock, par value $0.0001 | 8.8% | $7,113,107 | -$117,272,169 | 844,787 | -94% | ORBIMED ADVISORS LLC | 08 Apr 2026 |
| FBRX | Forte Biosciences, Inc. | Common Stock, par value $0.001 per share | 8% | $3,763,800 | 510,000 | ORBIMED ADVISORS LLC | 31 Dec 2024 | ||
| MBX | MBX Biosciences, Inc. | COMMON STOCK | 7.7% | $118,413,222 | -$11,880,750 | 3,637,887 | -9.1% | ORBIMED ADVISORS LLC | 05 Feb 2026 |
| AVBP | ArriVent BioPharma, Inc. | Common Stock | 7.5% | $66,692,036 | 3,027,328 | ORBIMED ADVISORS LLC | 11 Aug 2025 | ||
| NSPR | InspireMD, Inc. | Common Stock, par value $0.0001 per share | 7.4% | $5,577,461 | +$1,780,000 | 3,133,405 | +47% | ORBIMED ADVISORS LLC | 31 Dec 2025 |
| IKNA | ImageneBio, Inc. | COMMON STOCK | 6.9% | $820,179 | -$7,669,269 | 773,754 | -90% | ORBIMED ADVISORS LLC | 25 Jul 2025 |
| SION | Sionna Therapeutics, Inc. | Common Stock | 6.6% | $118,970,633 | -$29,554,504 | 2,967,722 | -20% | ORBIMED ADVISORS LLC | 15 Apr 2026 |
| NPCE | NeuroPace Inc | Common Stock, par value $0.001 per share | 6.2% | $27,569,330 | -$6,807,190 | 2,096,527 | -20% | OrbiMed Advisors LLC | 31 Mar 2026 |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | Common Stock, par value $0.0001 per share | 5.9% | $5,307,498 | 718,200 | OrbiMed Capital LLC | 31 Dec 2024 | ||
| CYBN | Cybin Inc. | Common Stock, no par value | 4.9% | 2,422,600 | ORBIMED CAPITAL LLC | 31 Dec 2025 | |||
| TERN | Terns Pharmaceuticals, Inc. | Common Stock | 4.8% | $31,842,911 | 4,240,068 | ORBIMED ADVISORS LLC | 03 Nov 2025 | ||
| IRON | Disc Medicine, Inc. | Common Stock | 4.5% | $73,382,798 | 1,556,369 | ORBIMED ADVISORS LLC | 10 Mar 2025 | ||
| FBRX | Forte Biosciences, Inc. | Common Stock, par value $0.001 per share | 4.3% | 884,230 | ORBIMED ADVISORS LLC | 31 Mar 2026 | |||
| PASG | Passage BIO, Inc. | COMMON STOCK | 4.2% | $53,029 | -$44,595 | 132,473 | -46% | ORBIMED ADVISORS LLC | 22 Jul 2025 |
| VTGN | Vistagen Therapeutics, Inc. | Common Stock, par value $0.001 per share | 4.2% | $1,213,378 | 1,639,700 | 0% | ORBIMED CAPITAL LLC | 31 Dec 2025 | |
| ADCT | ADC Therapeutics SA | Common Shares, par value CHF 0.08 per share | 2.6% | $11,953,949 | -$765,959 | 3,230,797 | -6% | ORBIMED CAPITAL LLC | 31 Dec 2025 |
| VSTM | Verastem, Inc. | Common Stock, par value $0.0001 per share | 2.4% | $6,319,998 | -$7,248,005 | 1,333,333 | -53% | ORBIMED ADVISORS LLC | 30 Jun 2025 |
| CTMX | CytomX Therapeutics, Inc. | Common Stock, par value $0.00001 per share | 2.1% | $15,160,295 | -$21,224,155 | 3,525,650 | -58% | OrbiMed Advisors LLC | 31 Dec 2025 |
| AVTX | Avalo Therapeutics, Inc. | Common Stock, par value $0.001 per share | 2.1% | $6,847,128 | -$10,261,865 | 475,165 | -60% | OrbiMed Advisors LLC | 31 Mar 2026 |
| XFOR | X4 Pharmaceuticals, Inc | Common Stock, par value $0.001 per share | 1.7% | $25,640 | 134,947 | ORBIMED ADVISORS LLC | 30 Jun 2025 | ||
| CCCC | C4 Therapeutics, Inc. | Common Stock, par value $0.0001 per share | 1% | $1,687,550 | -$5,127,991 | 883,534 | -75% | OrbiMed Capital LLC | 31 Dec 2025 |
| PMVP | PMV Pharmaceuticals, Inc. | COMMON STOCK | 0% | $0 | -$6,219,114 | 0 | -100% | ORBIMED ADVISORS LLC | 02 Mar 2026 |
| RAPT | RAPT Therapeutics, Inc. | Common Stock, par value $0.0001 per share | 0% | $0 | -$1,130,083 | 0 | -100% | ORBIMED ADVISORS LLC | 31 Mar 2026 |
| XTNT | Xtant Medical Holdings, Inc. | COMMON STOCK | 0% | $0 | 0 | ORBIMED ADVISORS LLC | 10 Apr 2025 |
Schedules 13D/G Reported by ORBIMED ADVISORS LLC:
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.